Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis

Journal of Lipid Research

Volumn 56, Issue 1, 2015, Pages 185-192

  Loomba, Rohit ^a,b   Quehenberger, Oswald ^b,c   Armando, Aaron ^c   Dennis, Edward A ^b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c San Diego   (United States)

Author keywords

Cirrhosis; Diagnostic test accuracy; Eicosanoid profiling; Hepatic steatosis; Liver disease; Mass spectrometry; Nonalcoholic fatty liver disease

Indexed keywords

11,12 DIHYDROXYEICOSATRIENOIC ACID; 20 CARBOXY ARACHIDONIC ACID; 3,14 DIHYDRO 15 KETOPROSTAGLANDIN D2; BIOLOGICAL MARKER; ICOSANOID; ICOSATRIENOIC ACID; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; LIPIDOMICS; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; BLOOD; METABOLISM; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHENOTYPE;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; EICOSANOIDS; FEMALE; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE;

EID: 84920509623     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P055640     Document Type: Article

References (32)

1. Chalasani, N., Z. Younossi, J. E. Lavine, A. M. Diehl, E. M. Brunt, K. Cusi, M. Charlton, and A. J. Sanyal. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 55: 2005-2023.
2. Browning, J. D., and J. D. Horton. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114: 147-152.
3. Adams, L. A., J. F. Lymp, J. St Sauver, S. O. Sanderson, K. D. Lindor, A. Feldstein, and P. Angulo. 2005. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 129: 113-121.
4. Matteoni, C. A., Z. M. Younossi, T. Gramlich, N. Boparai, Y. C. Liu, and A. J. McCullough. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116: 1413-1419.
5. Singh, S., A. M. Allen, Z. Wang, L. J. Prokop, M. H. Murad, and R. Loomba. 2014. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. (Epub ahead of print). April 22, 2014; doi:10.1016/j.cgh.2014.04.014.
6. Noureddin, M., and R. Loomba. 2012. Nonalcoholic fatty liver disease: indications for liver biopsy and noninvasive biomarkers. Clin. Liver Dis. 1: 104-107.
7. Rockey, D. C., S. H. Caldwell, Z. D. Goodman, R. C. Nelson, A. D. Smith; American Association for the Study of Liver Diseases. 2009. Liver biopsy. Hepatology. 49: 1017-1044.
8. Alkhouri, N., L. J. Dixon, and A. E. Feldstein. 2009. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3: 445-451.
9. Malhi, H., and G. J. Gores. 2008. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 360-369.
10. Puri, P., R. A. Baillie, M. M. Wiest, F. Mirshahi, J. Choudhury, O. Cheung, C. Sargeant, M. J. Contos, and A. J. Sanyal. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 46: 1081-1090.
11. Feldstein, A. E., N. W. Werneburg, A. Canbay, M. E. Guicciardi, S. F. Bronk, R. Rydzewski, L. J. Burgart, and G. J. Gores. 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 40: 185-194.
12. Puri, P., M. M. Wiest, O. Cheung, F. Mirshahi, C. Sargeant, H. K. Min, M. J. Contos, R. K. Sterling, M. Fuchs, H. Zhou, et al. 2009. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 50: 1827-1838.
13. Feldstein, A. E., R. Lopez, T. A. Tamimi, L. Yerian, Y. M. Chung, M. Berk, R. Zhang, T. M. McIntyre, and S. L. Hazen. 2010. Mass spectrometric profi ling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Lipid Res. 51: 3046-3054.
14. Zein, C. O., R. Lopez, X. Fu, J. P. Kirwan, L. M. Yerian, A. J. McCullough, S. L. Hazen, and A. E. Feldstein. 2012. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 56: 1291-1299.
15. Dumlao, D. S., M. W. Buczynski, P. C. Norris, R. Harkewicz, and E. A. Dennis. 2011. High- throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim. Biophys. Acta. 1811: 724-736.
16. Quehenberger, O., and E. A. Dennis. 2011. The human plasma lipidome. N. Engl. J. Med. 365: 1812-1823.
17. Quehenberger, O., A. M. Armando, A. H. Brown, S. B. Milne, D. S. Myers, A. H. Merrill, S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51: 3299-3305.
18. Noureddin, M., J. Lam, M. R. Peterson, M. Middleton, G. Hamilton, T. A. Le, R. Bettencourt, C. Changchien, D. A. Brenner, C. Sirlin, et al. 2013. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 58: 1930-1940.
19. Permutt, Z., T. A. Le, M. R. Peterson, E. Seki, D. A. Brenner, C. Sirlin, and R. Loomba. 2012. Correlation between liver histology and novel magnetic resonance imaging in adult patients with nonalcoholic fatty liver disease-MRI accurately quantifi es hepatic steatosis in NAFLD. Aliment. Pharmacol. Ther. 36: 22-29.
20. Le, T. A., J. Chen, C. Changchien, M. R. Peterson, Y. Kono, H. Patton, B. L. Cohen, D. Brenner, C. Sirlin, R. Loomba, et al. 2012. Effect of colesevelam on liver fat quantifi ed by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 56: 922-932.
21. Kleiner, D. E., E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell, Y. C. Liu, M. S. Torbenson, A. Unalp-Arida, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41: 1313-1321.
22. Tang, A., J. Tan, M. Sun, G. Hamilton, M. Bydder, T. Wolfson, A. C. Gamst, M. Middleton, E. M. Brunt, R. Loomba, et al. 2013. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 267: 422-431.
23. Patel, N. S., M. R. Peterson, D. A. Brenner, E. Heba, C. Sirlin, and R. Loomba. 2013. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fi brosis in nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 37: 630-639.
24. Loomba, R., T. Wolfson, B. Ang, J. Booker, C. Behling, M. Peterson, M. Valasek, G. Lin, D. Brenner, A. Gamst, et al. 2014. Magnetic resonance elastography predicts advanced fi brosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. (Epub ahead of print). October 29, 2014; doi:10.1002/hep.27362.
25. Patel, N. S., I. Doycheva, M. R. Peterson, J. Hooker, T. Kisselva, B. Schnabl, E. Seki, C. B. Sirlin, and R. Loomba. 2014. Effect of weight loss on MRI estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. (Epub ahead of print). September 13, 2014; doi:10.1016/j.cgh.2014.08.039.
26. Quehenberger, O., T. Yamashita, A. M. Armando, E. A. Dennis, and W. Palinski. 2011. Effect of gestational hypercholesterolemia and maternal immunization on offspring plasma eicosanoids. Am. J. Obstet. Gynecol. 205: 156.e15-156.e25.
27. Buczynski, M. W., D. S. Dumlao, and E. A. Dennis. 2009. Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 50: 1015-1038.
28. Imig, J. D., and B. D. Hammock. 2009. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8: 794-805.
29. Fang, X., F. M. Faraci, T. L. Kaduce, S. Harmon, M. L. Modrick, S. Hu, S. A. Moore, J. R. Falck, N. L. Weintraub, and A. A. Spector. 2006. 20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: role of cyclooxygenase. Am. J. Physiol. Heart Circ. Physiol. 291: H2301-H2307.
30. Lomonaco, R., C. Ortiz-Lopez, B. Orsak, A. Webb, J. Hardies, C. Darland, J. Finch, A. Gastaldelli, S. Harrison, F. Tio, et al. 2012. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 55: 1389-1397.
31. Fabbrini, E., S. Sullivan, and S. Klein. 2010. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 51: 679-689.
32. Kumashiro, N., T. Yoshimura, J. L. Cantley, S. K. Majumdar, F. Guebre-Egziabher, R. Kursawe, D. F. Vatner, I. Fat, M. Kahn, D. M. Erion, et al. 2013. Role of patatin-like phospholipase domaincontaining 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology. 57: 1763-1772.